September 30, 2020 07:38 AM EDT
R&D
FDA+

Dis­trict Court throws out Cat­a­lyst law­suit al­leg­ing im­prop­er ap­proval stan­dards for ri­val LEMS drug

Max Gelman

Senior Editor

Cat­a­lyst Phar­ma­ceu­ti­cals re­ceived bad news Tues­day af­ter­noon as a fed­er­al judge threw out their law­suit ac­cus­ing the FDA of il­le­gal­ly ap­prov­ing a ri­val drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times